In fact, the first in class sGC stimulator riociguat was approved in 2013 for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) (Ghofrani et al., 2017) and vericiguat completed successfully a pivotal phase 3 clinical trial in HF patients (Armstrong et al., 2020b) and was recently approved for HF treatment. Here, SGCB is linked to chronic thromboembolic pulmonary hypertension.